Chau is Partner at OrbiMed Advisors and since 2003 has principally focused on Venture Capital investments. Over his investment career, Chau has extensive experience in financing research and development of new medicines and therapeutic devices at all stages, across different drug modalities, and a range of disease areas from oncology to infectious diseases to ophthalmology. He is or has been a Board representative at companies such as Intercept Pharma and Intellia. Prior to OrbiMed, he developed skills in start-up operations and business development at Veritas Medicine, Inc. and in immunology research at the Yale School of Medicine and Massachusetts General Hospital. Chau holds a B.S. in molecular, cellular and developmental biology and M.P.H. with concentration in infectious disease, both from Yale University.